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Abstract
Recently, the potential of remnant thyroid ablation using 1,110 MBq 131I has been established, albeit under 
certain limitations, and guidelines have been issued on its use as an outpatient procedure in Japan. The aims of 
this study were to calculate the success rate of remnant thyroid ablation with 1,110 MBq as an outpatient proce-
dure in high-risk differentiated thyroid carcinoma (DTC) patients and explore the relationship between successful 
outcome and patient-/disease-related factors. Fifty high-risk patients with DTC underwent remnant thyroid abla-
tion with 1,110 MBq 131I on an outpatient basis between January 2009 and March 2011 at Tokyo Medical Univer-
sity Hospital. The ablation success rate was evaluated using a whole body scan (WBS) performed at 4-33 
months (mean, 7 months) post-
successful outcome was obtained in 41 patients, with a success rate of 82.0%, which was in agreement with that 
any patient-/disease-related factor. We believe that remnant ablation with 1,110 MBq 131I in high-risk DTC 
ablation with low-dose (1,110 MBq) 131I in high-risk DTC patients.
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Introduction
Patients with high-risk differentiated thyroid carci-
noma (DTC) are typically treated with total thyroidec-
tomy (TT) followed by 131I ablation of the post-surgical 
thyroid remnant in accordance with the Japanese clinical 
guidelines1). Ablation of remnant thyroid tissue is also 
recommended by international consensus in high-risk 
patients2)3). The purpose of this procedure is to remove 
completely any remaining thyroid tissue following TT. 
This has been reported to improve disease-free survival 
and local control rate in high-risk patients4). The level 
of iodine in the Japanese diet differs from that found in 
Europe or the United States, resulting in a higher rate of 
occurrence of papillary carcinoma. Therefore, surgery 
involves neck lymph node dissection due to the greater 
number of lymph node metastases. However, fewer 
distant metastases occur with this disease than usually 
found with follicular carcinoma. Some studies have 
noted that there is a lack of hospital wards and beds 
available for non-sealed radioiodine therapy5)6). Based 
on these two points, remnant thyroid ablation has often 
been avoided in some DTC patients in Japan for a long 
time. Recently, guidelines have been established on 
remnant thyroid ablation as an outpatient procedure, with 
ablation using 1,110 MBq 131I becoming possible, albeit 
under certain limitations7)8). The aims of this study were 
to calculate the success rate of remnant thyroid ablation 
with 1,110 MBq as an outpatient procedure in high-risk 
DTC patients and explore the relationship between suc-
cessful outcome and patient-/disease-related factors (age, 
sex, pT stage, presence of lymph node metastasis, dura-
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tion from TT to ablation). To our knowledge, this is the 
Materials and Methods
1. Patients
Fifty high-risk patients with DTC underwent remnant 
thyroid ablation with 1,110 MBq 131I on an outpatient 
basis between January 2009 and March 2011 at Tokyo 
Medical University Hospital. Patient characteristics are 
shown in Table 1. All patients underwent TT as radical 
surgery and comprised 36 female and 14 male, with a 
mean age at ablation of 53.9 years. The diagnosis was 
-
cation of pT2 in 1 patient, pT3 in 33, and pT4 in 16. 
Among 40 cases of lymph node metastasis, 38 were 
pN1b and 2 were pN1a. The mean duration from TT to 
ablation was 245.5 days (range 53-1327 days). High 
risk was defined according to the following criteria : 
tumor size larger than 5 cm ; lymph node metastasis 
larger than 3 cm ; lymph node metastasis extending to 
the internal jugular vein, carotid artery, or major nerves 
such as the recurrent laryngeal nerve or pre-vertebral 
fascia ; multiple and intensely swollen lymph node 
metastases ; or extra-thyroid extension to the trachea or 
esophageal mucosa1). Exclusion criteria were the pres-
ence of distant metastases (e.g., lung or bone) or a treat-
ment history of 131I thyroid ablation.
2. Radioiodine ablation of remnant thyroid
All patients underwent remnant thyroid ablation with 
1,110 MBq 131I. Administration of levothyroxine was 
withdrawn for 4 weeks and replaced with triiodothyro-
preparation for the procedure. The patients were 
instructed to follow a low-iodine diet for 2 weeks prior 
to surgery until the 4-5th day after ablation. No recom-
binant human TSH (rhTSH) was used for the ablation. 
The TSH and serum Tg values were measured in all 
patients at ablation. Four days after oral administration 
-camera equipped 
with high-resolution parallel-hole collimator (E.CAM, 
Siemens, Erlangen, Germany). Whole body planar 
images and spot views of the neck were acquired in ante-
rior and posterior projections on a photo peak of 365 keV 
with a 15% window.
3. Evaluation
Post-ablation WBS was performed at 4-33 (mean, 7 
months) months after the ablation. WBS and serum Tg 
value measurement were performed either thyroid hor-
mone withdrawal (THW) or rhTSH-aided9). WBS by 
THW was obtained on the fourth day with 481-1,110 
MBq of 131I with measurement of Tg value on the first 
day. On the other hand, by rhTSH-aided protocol, 
rhTSH was given at a dose of 0.9 mg intramuscularly on 
day 1, and day 2. On the day 3, 185-1,110 MBq of 131I 
was administered. On day 5 or 6, WBS was performed 
of ablation was negative of WBS. 
4.  Statistical analysis (multiple logistec-regression 
analysis)
For statistical analysis, we used SPSS version 17.0 for 
Windows (SPSS Inc, Chicago, Illinois, USA). The 
quantitative data (continuous parameters) were analyzed 
using the forward selection method of likelihood ratio 
test. We selected as variable factors of age, gender, pT 
stage, presence of lymph node metastasis, duration from 
difference was considered when p value of <0.05 was 
considered to indicate a statistically significant differ-
ence.
Results
The success rate of remnant thyroid ablation was 82% 
in 41 of 50 patients (Fig. 1). The procedure was deemed 
to have failed in the remaining 9 patients based on their 
post-ablation WBS results (Fig. 2). The presence of 
thyroid tissue in the thyroid bed was indicated in these 
patients and additional ablation therapy administered. 
There were no cases of local recurrence or cancer death 
during the study period. On the other hand, a high Tg 
value (ranging from 20 to 210 ng/ml) was observed in 7 
patients during the post-ablation follow-up and cervical 
lymph node and/or pulmonary metastases confirmed, 
indicating the need for additional treatment. 
In the multiple logistic- -
cant correlation was observed between the success of 
remnant thyroid ablation and age, sex, pT stage, lymph 
node metastases, or duration from TT to ablation (Table 
2). The goodness-of-fit in this model was verified by 
the Hosmer-Lemeshow test (p=0.671).
Discussion
Differentiated thyroid carcinoma is the most common 
endocrine malignancy. The 10-year survival rate is 
reported to be 93% in papillary carcinoma and 85% in 
follicular carcinoma according to a large cohort study in 
the USA10). The diagnosis in patients with DTC is also 
good. For high-risk DTC, TT is recommended under 
the Japanese guidelines1). A multivariate analysis of 
over 50,000 patients with papillary thyroid carcinoma 
revealed that TT significantly improved recurrence and 
survival rates for tumors >1.0 cm11). Remnant thyroid 
ablation increases the rates of local control and cause-
specific survival rates, especially in high-risk patients 
undergoing TT4).
Thyroid tissue remains in approximately 90% of 
patients undergoing TT, but is often impossible to detect 
by various imaging modalities such as ultrasonography 
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Table 1 Patient characteristics and clinical data
Number Age Sex pT stage pN status Total thyroidectomy to ablation (day)
Pre-ablation Tg
(ng/ml)
Post-ablation Tg
(ng/ml) WBS
1 72 F T3 N1a 359  2 undetectable negative
2 35 M T3 N1b 120  4  2 negative
3 69 M T4 N1b 126  37 230 negative
4 48 F T4 N1b 102  2 undetectable negative
5 27 F T3 N1b  88  2 undetectable negative
6 77 F T4 N1b 217  3 undetectable negative
7 22 F T3 N1b 155  16  2 negative
8 51 F T3 N1b 231  4 undetectable negative
9 39 M T3 N1b 199  5 undetectable negative
10 63 F T3 N1b 197  2 undetectable negative
11 62 F T3 N1b 154  2 undetectable negative
12 66 M T4 N1b 239  5  2 negative
13 43 F T3 N0 973  2 undetectable negative
14 57 F T3 N0 61 undetectable undetectable negative
15 36 F T4 N0 151 undetectable undetectable negative
16 49 M T3 N1b 113 undetectable undetectable negative
17 71 F T4 N0 365  2  2 negative
18 39 F T3 N1b 245  81  60 negative
19 46 F T3 N1b 156  21  5 negative
20 71 F T4 N1b 204  66  42 negative
21 79 F T4 N× 1,327  74  37 negative
22 23 F T3 N1b 119  9  3 negative
23 40 M T3 N1b 100 202  99 negative
24 71 M T4 N0 690 undetectable undetectable negative
25 64 M T4 N1b 161  50 210 negative
26 78 F T3 N1b 219  40  21 negative
27 64 F T3 N1b 53  49  35 negative
28 62 M T4 N1b 203  11  6 negative
29 19 F T3 N1b 122  21  7 negative
30 76 F T3 N1b 260 undetectable undetectable negative
31 63 F T2 N1a 211 undetectable undetectable negative
32 52 M T3 N1b 166 369 152 negative
33 59 F T3 N1b 543 174 160 negative
34 61 F T3 N1b 263  30  20 negative
35 80 F T3 N0 393  2 undetectable negative
36 38 F T3 N1b 105  38  26 negative
37 71 F T4 N0 147 undetectable undetectable negative
38 55 F T3 N1b 870 undetectable undetectable negative
39 38 F T3 N1b 155  63  27 negative
40 37 F T4 N1b 102 134 162 negative
41 80 F T4 N0 274 undetectable  2 negative
42 41 F T3 N1b 216  3 undetectable positive
43 58 M T4 N1b 141  70  27 positive
44 43 F T3 N1b 147  57  11 positive
45 56 F T3 N0 204 undetectable undetectable positive
46 23 M T4 N1b 97 136 118 positive
47 76 M T3 N1b 161  17  10 positive
48 45 F T3 N1b 77  7  2 positive
49 62 M T3 N1b 106  34  29 positive
50 37 F T3 N1b 190 undetectable undetectable positive
*Tg undetectable mean <1 ng/ml
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and CT scans. Ablation with 131I offers an effective 
method of destroying remnant thyroid tissue, reducing 
the possibility of local recurrence. Moreover, this 
method is more suitable than other procedures as it is 
convenient for use during post-surgical follow-up. The 
serum Tg value is a good marker of recurrence and dis-
tant metastases during post-surgical follow-up in DTC 
patients as it does not require anti-thyroglobulin anti-
body. However, the serum Tg value cannot be deter-
mined if thyroid tissue remains. As ablation erases Tg 
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Table 2 Patient characteristics and multiple logistic-regression analysis of predictive factors for successful ablation
Succcess Failure P value
Sex 0.243
Male 10 4
Female 31 5
Age 0.364
Mean (range 55.0 (19.0-80.0) 49.0 (23.0-76.0)
p Tstage* 0.46
T3 26 7
T4 14 2
Presence of lymph node metastases** 0.444
N0  8 1
N1a-b 32 8
Total thyroidectomy to ablation (day) 0.18
Mean (SD) 258.5±266.8 148.8±46.1
Range 53.0-1,327.0 77.0-216.0
Quantitative data (continuous parameters) were analyzed using forward selection method of likelihood ratio test. No 
lymph node metastases, or duration from TT to ablation.
*Excluding one case of T2 
**Excluding one case of Nx
Fig. 1. Successful case (Case 8 in Table 1)
 a : WBS on 5th day of ablation. Intense uptake of 131I in center of neck, indicating thyroid bed accumulation.
 b : Post-ablation WBS using 1,110 MBq 131I performed at 20 months after ablation. There was no accumulation in thyroid 
bed. Tg value decreased from 4 to undetectable level after ablation. This case was considered to be successful.
a b
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from remnant thyroid tissue, its serum values can serve 
as a good marker of post-surgical recurrence or metasta-
sis. Therefore, it is important for patients at high risk of 
post-surgical recurrence or metastasis to undergo abla-
tion12-16).
Even allowing for differences in high-risk patients or 
dosage of 131I, the success rate of ablation is approxi-
mately 70%-95%17)18). Zidan et al. reported the ablation 
success rate as 94% in 238 patients receiving 1,110-3,145 
MBq. Bal et al. reported the success rate as 72.8% in 
149 patients receiving 1,110-5,735 MBq. In the present 
study, remnant thyroid ablation with 1,110 MBq in high-
risk patients yielded an equivalent therapeutic result to 
as a negative WBS result, as the purpose of remnant thy-
roid ablation is to destroy the remnant thyroid bed. 
After TT and ablation, the serum Tg value is normally 
-presence 
of remnant thyroid tissue and investigate metastatic or 
recurrent lesions. A high Tg value with negative neck 
accumulation is thought to suggest microscopic metasta-
ses in extra-thyroid lesions. During observation, cervi-
cal lymph node and/or pulmonary metastases were found 
in 7 patients with high a Tg value by chest CT or neck 
ultrasonography. There is a real potential of local recur-
rence or metastasis, so careful diagnostic imaging and 
observation are needed. If local recurrence or distant 
metastases actually occur, then additional therapy is 
needed. There is no effective chemotherapy for local 
recurrent or distant metastases in DTC patients. It is 
difficult to control tangible local recurrences or lymph 
node metastases detected on imaging studies, so surgical 
treatment is the most appropriate response19).
Recently, few studies have reported any difference in 
the ablation success rate between low-dose (1,110 MBq) 
and high-dose (3,700 MBq) 131I20-22). In this study, we 
administered 1,110 MBq on the basis of the established 
guidelines for outpatient treatment. We believe that the 
present results obtained with a low dose are of particular 
interest.
We analyzed the relationship between patient-/dis-
ease-related factors and ablation success. No signifi-
cant correlation was observed between the success of 
remnant thyroid ablation and age, sex, pT stage, or pres-
ence of lymph node metastasis. No correlation was 
observed between ablation success and the duration from 
TT to ablation. To our knowledge, no studies to date 
have established the appropriate duration from TT to 
remnant thyroid ablation. However, the risk of death in 
patients undergoing initial radioiodine therapy at more 
than 180 days after TT is reported to be 4.22 times higher 
than that in those treated within 180 days in metastatic 
DTC23).
There was small number of failure cases in this study. 
5
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Fig. 2. Failure case (Case 48 in Table 1)
 a : WBS on 5th of ablation. Intense uptake of 131I in center of neck, indicating thyroid bed accumulation.
 b : Post-ablation WBS using 1,110 MBq 131I performed at 6 months after ablation.
 Neck accumulation remained. Presence of thyroid tissue in thyroid bed was suggested.
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Further study is needed to elucidate the relationship 
between the success of ablation and such factors in larger 
samples of patients. 
Conclusion
The success rate of remnant thyroid ablation was 82% 
in 41 of 50 patients, which is in agreement with rates 
reported in earlier studies. The present results suggest 
that the success of remnant thyroid ablation is indepen-
dent of age, sex, pT stage, presence of lymph node 
metastases, or duration from TT to ablation.
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